

January 23, 2025

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 543322

Ref: Scrip Name: ALIVUS

Dear Sirs,

Sub: Press Release

Pursuant to regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, we are enclosing herewith the Press Release on the Unaudited Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2024.

You are requested to take the same on record.

Thanking You.

Yours faithfully,
For Alivus Life Sciences Limited
(Formerly known as Glenmark life Sciences Limited)

Rudalf Corriea
Company Secretary & Compliance Officer
Encl: As above

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited)

Corporate Office:

4th Floor, OIA House, 470, Cardinal Gracious Road
Andheri (E), Mumbai 400 099, Maharashtra, India

Registered Office:

Plot No 170-172, Chandramouli Industrial Estate
Mohol Bazarpeth, Solapur 413 213, India

T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@glenmarklifesciences.com | W: www.alivus.com



PRESS RELEASE

For Immediate dissemination



Alivus Life Sciences Reports Strong Q3FY25 Results, Delivers 12% Revenue Growth

EBITDA margins expand to 31.3%

Mumbai, January 23, 2025: Alivus Life Sciences Limited (Formerly Glenmark Life Sciences Limited), a leading developer and manufacturer of select, high-value, non-commoditized, Active Pharmaceutical Ingredients (APIs) in chronic therapeutic areas, today announced its financial results for the quarter and nine months ended December 31, 2024.

Revenue from operations for Q3FY25 reached Rs. 6,418 Mn, a growth of 12.0% YoY and 26.6% QoQ. For 9MFY25, revenue from operations was Rs. 17,373 Mn.

For Q3FY25, EBITDA was at Rs. 2,008 Mn, a growth of 15.2% YoY and 40.5% QoQ. EBITDA margins were at 31.3%, up 90 bps YoY and 310 bps QoQ. EBITDA for 9MFY25 was at Rs. 5,086 Mn while EBITDA margins stood at 29.3%.

PAT for the quarter stood at Rs. 1,370 Mn and PAT margins were at 21.3%. For 9MFY25, the company recorded PAT of Rs. 3,438 Mn with PAT margins of 19.8%.

During 9MFY25, the company generated a strong free cash flow of Rs. 1,838 Mn leading to Cash and Cash Equivalents (including short term investments) of Rs. 4,993 Mn as of 31 December 2024.

Commenting on the company's performance Dr. Yasir Rawjee, MD & CEO, Alivus Life Sciences Limited said, *"The start of the new year marks a notable shift for us as we transition to Alivus Life Sciences.*

I am pleased to report that our Q3 performance reflects this renewed energy, with growth across both GPL and Non-GPL segments. Geographically, regions like India, Europe, ROW and Japan contributed to the growth.

Our quest for high-quality, innovative solutions and scalability continues, in order to build a sustainable business over the long term."

Tushar Mistry, CFO, Alivus Life Sciences Limited said, *"Our emphasis on achieving quality growth has delivered encouraging outcomes with highest ever quarterly revenue at Rs. 6,418 Mn. This translated to steady gross margins at ~56%, while our EBITDA grew by 15.2% YoY, underscoring our ability to cater a diversified product range while maintaining stringent cost efficiency."*

Additional Highlights:

- DMF / CEPs filing continues across major markets, taking the total cumulative filings to 548 as on 31 December 2024
- In Q3FY25, two synthetic small molecules were included to the development grid
- The HP API portfolio has 21 APIs in the active grid with six products validated and six products in advanced stages of development.

Capex Update:

Solapur – Phase 1 construction work has started for 200 KL capacity.

PRESS RELEASE

For Immediate dissemination



About Alivus Life Sciences Ltd (ALIVUS)

Alivus Life Sciences Limited (Formerly Glenmark Life Sciences Limited) (BSE: 543322, NSE: ALIVUS), is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes. The company is increasingly providing CDMO services to a range of multinational and specialty pharmaceutical companies. It has a diversified portfolio of 161 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan, and the Rest of the World (RoW).

The company's four manufacturing facilities are located in Ankleshwar, Dahej, Mohol and Kurkumbh with a total installed capacity of 1424 KL, which are regularly inspected by global regulators such as USFDA, PMDA (Japan) and EDQM (Europe). Alivus Life Sciences is listed on BSE and NSE.

Learn more about Alivus Life Sciences Limited on <https://www.alivus.com>

For any further queries please contact:

Soumi Rao | General Manager – Corporate Communications

Email: Soumi.Rao@glenmarklifesciences.com

Mobile: 98701 96931

Ernst & Young LLP – Investor Relations

Diwakar Pingle

Email: Diwakar.Pingle@in.ey.com

Runjhun Jain

Email: Runjhun.Jain1@in.ey.com

Sneha Salian

Email: Sneha2.Salian@in.ey.com